Olmesartan Plus Hct Eg (Olmesartan Medoxomil, Hydrochlorothiazide)

Olmesartan medoxil, the active ingredient in Olmesartan Plus Hct Eg, is an Angiotensin II receptor blocker presented as an oral tablet for oral use. It lowers elevated blood pressure and is combined with a thiazide diuretic to enhance antihypertensive effect in adult patients.

GNH USA supplies Olmesartan Plus Hct Eg as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides reliable global distribution.

Olmesartan Plus Hct Eg is used to manage hypertension, acting on the renin‑angiotensin‑aldosterone system to lower systemic blood pressure.

- Hypertension: reduces systolic and diastolic blood pressure in patients with essential hypertension. - Hypertension with fluid retention: provides additional diuretic effect to control edema. - Hypertension requiring combination therapy: simplifies treatment by combining an ARB with a thiazide diuretic.

Common and serious adverse reactions have been reported with Olmesartan Plus Hct Eg.

Common Side Effects: - Dizziness: transient light‑headedness, especially after initial dosing. - Headache: mild to moderate cranial pain. - Fatigue: general feeling of tiredness. - Increased urination: due to the thiazide component.

Serious or Rare Side Effects: - Angioedema: swelling of face, lips, tongue, or airway. - Severe dehydration: excessive fluid loss leading to low blood pressure. - Acute kidney injury: sudden decline in renal function. - Hyperkalemia: elevated blood potassium levels.

Before prescribing Olmesartan Plus Hct Eg, clinicians should consider several safety precautions.

- Renal function monitoring: assess serum creatinine and eGFR regularly. - Electrolyte balance: check potassium and sodium levels due to thiazide effect. - Pregnancy avoidance: contraindicated in the second and third trimesters. - Hepatic impairment: use with caution in patients with liver disease. - Gradual discontinuation: avoid abrupt cessation to prevent rebound hypertension. - Store at room temperature: keep in original packaging, protect from moisture and light.

Olmesartan Plus Hct Eg may interact with other medicines, requiring dose adjustments or avoidance.

Major Interactions (Avoid): - Aliskiren (in diabetic patients): increased risk of renal impairment. - Potassium‑sparing diuretics: risk of hyperkalemia. - ACE inhibitors or other ARBs: additive effect on potassium and blood pressure. - Lithium: increased lithium toxicity. - NSAIDs (high dose): may reduce antihypertensive efficacy and impair renal function.

Moderate Interactions (Monitor Closely): - Other thiazide diuretics: additive diuretic effect, monitor electrolytes. - Antihypertensive agents (beta‑blockers, calcium channel blockers): may cause excessive blood pressure lowering. - CYP450 inhibitors (e.g., fluconazole): possible increase in olmesartan levels. - Antacids containing aluminum or magnesium: may affect absorption of olmesartan. - Beta‑agonists (e.g., albuterol): may reduce antihypertensive response.